Save
esh.org
Sickle cell disease pathophysiology
ESH eLearning, Jacques Elion, 219038
Thalassaemias
ESH eLearning, Maria Domenica Cappellini, 219039
Malaria and red cell disorders
ESH eLearning, Michael Lanzer, 219040
Epidemiology of red cell disorders
ESH eLearning, Frédéric B. Piel, 219041
Red cell senescence and storage lesions
ESH eLearning, Giel Bosman, 219042
Erythroid niche and erythroblast maturation
ESH eLearning, Mohandas Narla, 219034
Epigenetics in erythropoiesis
ESH eLearning, Gordon D. Ginder, 219035
Heme synthesis and iron metabolism
ESH eLearning, Laurent Gouya, 219036
Red cells and oxidative stress
ESH eLearning, Lucia De Franceschi, 219037
Richter transformation in the elderly patient:molecular origin and new strategies for improved therapies
ESH eLearning, Davide Rossi, 212197
Targeting the DNA Damage Response in high-risk lymphoma: biology and insights for future, less toxic approaches of therapy
ESH eLearning, Reinhardt Christian, 212198
Double hit and other types of high-risk lymphoma:molecular features and optimal management in the elderly patient
ESH eLearning, Paul Hamlin, 212199
Biology of AML at older age
ESH eLearning, Terrence N. Wong, 212185
Therapeutic management of the so-called “fit” older patient with AML
ESH eLearning, Bob Löwenberg, 212186
Management of the unfit patient with AML
ESH eLearning, Gert Ossenkoppele, 212187
The older patient with ALL
ESH eLearning, Hervé Dombret, 212188
Alloegeneic stem cell transplantation at older age
ESH eLearning, Nicolaus Kröger, 212189
Clonal evolution of multiple myeloma
ESH eLearning, Nikhil Munshi, 212190
MGUS and MGUS transition to myeloma, what do we need to do?
ESH eLearning, Irene Ghobrial, 212191
Multiple myeloma in the elderly, a particular challenge in light of numerous novel agents.
ESH eLearning, Jesús F. San-Miguel, 212192
Clonal evolution in malignant lymphoma
ESH eLearning, Jude FITZGIBBON, 212193
Management of indolent lymphoma in the elderly patient
ESH eLearning, Loretta Nastoupil, 212194
Management of comorbidity and specific adverse events in the era of novel kinase inhibitors (ibrutinib, idelalisib, venetoclax) for lymphoid malignancies
ESH eLearning, Farrukh Awan, 212195
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma
ESH eLearning, Loretta Nastoupil, 212196
DNA damage, a driving force of aging
ESH eLearning, Björn Schumacher, 212174
Clonal hematopoiesis
ESH eLearning, Benjamin Ebert, 212175
Clonal hematopoiesis
ESH eLearning, George Vassiliou, 212176
Selection of TP53 mutant clones following chemotherapy
ESH eLearning, Terrence N. Wong, 212177
Aging stem cells and stress
ESH eLearning, Michael Milsom, 212178
Anemia at older age
ESH eLearning, Nancy Berliner, 212179
Microenvironment and MDS
ESH eLearning, Rebekka Schneider, 212180
Biology of MDS
ESH eLearning, Benjamin Ebert, 212181
Management of high grade MDS
ESH eLearning, Pierre Fenaux, 212182
Management of CMML and other MDS/MPN entities
ESH eLearning, Raphael Itzykson, 212183
Assessing the aging individual with hematologic disorders: How geriatric assessment can define the fitness of an older patient
ESH eLearning, Tanya Wildes, 212184
The pathology of marginal zone lymphomas
ESH eLearning, German Ott, 210034
Marginal zone lymphoma: biology and molecular genetics
ESH eLearning, Ming Qing Du, 210035
Marginal zone lymphoma. Prognostic models.
ESH eLearning, Carlos Montalban, 210036
Clinical aspects
ESH eLearning, Catherine Thieblemont, 210037
Treatment of splenic marginal zone lymphoma
ESH eLearning, Barbara Kiesewetter, 210038
Treatment of nodal marginal zone lymphoma
ESH eLearning, Catherine Thieblemont, 210039
Treatment of MALT lymphoma
ESH eLearning, Emanuele Zucca, 210040
Novel targeted therapies in CL - Ibrutinib
ESH eLearning, John Gribben, 210025
Idelalisib
ESH eLearning, Michael J. Keating, 210026
Venetoclax
ESH eLearning, Peter Hillmen, 210027
Follicular lymphoma; from genetics to pathogenesis
ESH eLearning, Riccardo Dalla-Favera, 210028
Clonal evolution of follicular lymphoma
ESH eLearning, Michael R. Green, 210029
Integrating molecular diagnostics for improved patient stratification in follicular lymphoma
ESH eLearning, Oliver Weigert, 210030
Advanced stage patient, first line
ESH eLearning, Christian Buske, 210031
Treatment of follicular lymphoma (FL): Salvage therapy
ESH eLearning, Vincent Ribrag, 210032
New agents
ESH eLearning, Gilles Salles, 210033
Micro RNA dysregulation to identify targets for therapy in hematopoietic malignancies
ESH eLearning, Carlo M. Croce, 210019
Genetic portrait of CLL
ESH eLearning, Cathy Wu, 210020
Predictive biomarkers in CLL
ESH eLearning, Davide Rossi, 210021
FCR
ESH eLearning, Michael J. Keating, 210022
BR
ESH eLearning, Olivier Tournilhac, 210023
Chlorambucil plus anti-CD20 MoAb
ESH eLearning, Valentin Goede, 210024
Myeloma Hub
ESH eLearning, ESH , 204612
iCMLf Prize talk
ESH eLearning, Jerry Radich, 205141
John Goldman Prize Talk
ESH eLearning, Tim Hughes, 205140
Janet Rowley Prize talk
ESH eLearning, Mhairi Copland, 205142
Targeting non-coding RNAs in leukemia
ESH eLearning, Ramiro Garzon, 204647
Exportin (XPO1) inhibitors for the treatment of AML
ESH eLearning, Ramiro Garzon, 204648
Novel targets for AML
ESH eLearning, Ramiro Garzon, 204649
The spliceosome mutations that can cause hematological malignancies
ESH eLearning, Omar Abdel-Wahab, 204650
Efficacy of first generation FLT3 inhibitors for AML
ESH eLearning, Miguel Sanz, 204651
The need for collaboration amongst hospitals: learning from RATIFY
ESH eLearning, Miguel Sanz, 204652
The importance of collaboration in AML research
ESH eLearning, Omar Abdel-Wahab, 204660
Neomorphic mutations driving hematological cancers
ESH eLearning, Omar Abdel-Wahab, 204661
Therapeutics targeting splicing in hematological malignancies
ESH eLearning, Omar Abdel-Wahab, 204662
What are the drivers of leukemia?
ESH eLearning, Omar Abdel-Wahab, 204663
The benefits of patient advocacy groups
ESH eLearning, Jane Churpek, 204664
Developing an understanding of disease progression in MDS and AML
ESH eLearning, Jane Churpek, 204665
Balancing hereditary research with patient care in leukemia
ESH eLearning, Jane Churpek, 204666
Combination therapies and improving overall survival in AML
ESH eLearning, Mark Levis, 204667
The challenges of using kinase inhibitors for AML treatment
ESH eLearning, Mark Levis, 204668
AML clinical trials: early stage vs. relapse/refractory patients
ESH eLearning, Marion Subklewe, 204676
T-cell engaging antibodies: what lessons have we learnt?
ESH eLearning, Marion Subklewe, 204677
Upcoming clinical trials for venetoclax chemotherapy combinations for AML
ESH eLearning, Marina Konopleva, 204678
Providing the relevant information to patients: a changing approach in Spain
ESH eLearning, Jorge Sierra, 204679
What are the alternative treatment options for relapsed or elderly AML patients?
ESH eLearning, Jorge Sierra, 204680
Cytokine release syndrome: a limiting factor for AML treatment
ESH eLearning, John DiPersio, 204681
Bispecific agents: the future of AML and MDS treatment?
ESH eLearning, John DiPersio, 204682
The problem of treating AML with CD123-targeting drugs
ESH eLearning, John DiPersio, 204683
The use of second generation FLT3 inhibitors for AML
ESH eLearning, Francesco Lo-Coco, 204692
The standardization of molecular diagnostics for myeloid diseases in Italy
ESH eLearning, Francesco Lo-Coco, 204693
New treatments for AML using inhibitors
ESH eLearning, Francesco Lo-Coco, 204694
The future of leukemia treatment in the elderly
ESH eLearning, John DiPersio, 204695
When to use bispecifics for AML
ESH eLearning, John DiPersio, 204696
Expanding trials using bispecifics
ESH eLearning, John DiPersio, 204697
The challenges facing elderly AML treatment
ESH eLearning, Lars Bullinger, 204698
Adapting AML treatment for elderly patients
ESH eLearning, Lars Bullinger, 204699
CAR T-cells and CRISPR: The future of AML treatment
ESH eLearning, Saar Gill, 204708
The development of novel treatment modalities: regulations and expectations
ESH eLearning, Saar Gill, 204709
Transferring lessons learnt from treating ALL to AML
ESH eLearning, Saar Gill, 204710
Price vs. performance: CAR T-cells
ESH eLearning, Saar Gill, 204711
The potential of differentiation therapies for AML
ESH eLearning, Stéphane de Botton, 204712
The next steps for the IDH2 inhibitor drug enasidenib
ESH eLearning, Stéphane de Botton, 204713
Working with smaller research companies
ESH eLearning, Stéphane de Botton, 204714
The future of AML and MDS diagnosis and treatment
ESH eLearning, Stéphane de Botton, 204715

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings